Independent directory Public ClinicalTrials.gov records United States
Location Directory

Clinical trials in Minneapolis, Minnesota

This page shows live ClinicalTrials.gov search results for Minneapolis, Minnesota, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 10:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
7879
Shown on this page
12
Current sort
Recently updated
Location scope
Minneapolis, MN
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Minneapolis, Minnesota. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 841–852 of 7,879 matching trials in Minneapolis, MN.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Live official records

Open in full search
Conditions
Fragile X Syndrome
Interventions
Low dose of MRM-3379, Middle Dose of MRM-3379, High dose of MRM-3379, Placebo, Low dose of MRM-3379 Open-Label
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
13 Years to 45 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
15
States / cities
Phoenix, Arizona • Irvine, California • Orange, California + 12 more
Conditions
Autologous Stem Cell Transplant, Classic Hodgkin Lymphoma
Interventions
Pembrolizumab, Autologous stem cell transplant, Carmustine, Etoposide, Cytarabine, Melphalan
Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Peripheral Artery Disease
Interventions
intermittent pneumatic compression, exercise, Sham device, Health Education
Device · Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
55 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
4
States / cities
Chicago, Illinois • Detroit, Michigan • Minneapolis, Minnesota
Conditions
Chemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Best Practice, Exercise Counseling, Exercise Intervention, Magnetic Resonance Imaging, Neuropathy Assessment, Questionnaire Administration
Other · Procedure
Lead sponsor
University of Rochester NCORP Research Base
Other
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
93
States / cities
Fresno, California • Martinez, California • Roseville, California + 70 more
Conditions
Eating Disorders
Interventions
HRV-bio, ED-JITAI
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 64 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Active, not recruiting No phase listed Observational

OCS DCD Heart + CAP Continued Follow-Up

NCT05741723
Conditions
Heart Transplant
Interventions
OCS Heart
Device
Lead sponsor
TransMedics
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Timeline
2019 – 2026
U.S. locations
20
States / cities
La Jolla, California • Palo Alto, California • New Haven, Connecticut + 15 more
Conditions
Gastrinoma, Glucagonoma, Insulinoma, Islet Cell Carcinoma, Pancreatic Polypeptide Tumor, Recurrent Islet Cell Carcinoma, Somatostatinoma
Interventions
temozolomide, capecitabine
Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
323
States / cities
Anaheim, California • Antioch, California • Baldwin Park, California + 221 more
Conditions
Acute Myocardial Infarction Type 1
Interventions
Deferiprone Tablets, Placebo
Drug
Lead sponsor
Rohan Dharmakumar
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
2
States / cities
Indianapolis, Indiana • Minneapolis, Minnesota
Conditions
Respiratory Syncytial Virus
Interventions
Placebo, mRNA-1345
Drug
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
60 Years and older
Enrollment
36,814 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
133
States / cities
Birmingham, Alabama • Guntersville, Alabama • Huntsville, Alabama + 114 more
Conditions
Melanoma (Skin)
Interventions
interferon alfa-2b, observation
Biological · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
1,150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2026
U.S. locations
511
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 354 more
Conditions
Hemophilia A
Interventions
Efanesoctocog Alfa BIVV001
Drug
Lead sponsor
Sanofi
Industry
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
28
States / cities
Gilbert, Arizona • Loma Linda, California • Los Angeles, California + 23 more
Conditions
Advanced Biliary Tract Cancer, Biliary Tract Cancer (BTC)
Interventions
Nanvuranlat, Physician's Best Choice
Drug · Other
Lead sponsor
J-Pharma Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
18
States / cities
Duarte, California • Orange, California • Santa Monica, California + 15 more